Growth strategies and dynamic products in the pipeline
Hong Kong, Apr 1, 2014 - (ACN Newswire) - Uni-Bio Science Group Limited ("Uni-Bio" or the "Group") (SEHK code: 690) strengthened the composition of the Board of Directors ("Board") and senior management team to enhance business fundamentals and to initiate new business development strategies. Operation and business restructuring initiatives will further optimise the Group's operations, providing a stronger platform to drive business growth.
Following the appointment of Mr. Kingsley Leung as an executive Director in February, Dr. Carl Firth and Mr. Zhao Zhi Gang have been appointed as independent non-executive Directors on 1 April 2014. Mr. Leung, Mr. Zhao and Dr. Firth have strong backgrounds in pharmaceuticals and biotechnology, and their industry and professional knowledge will enable the Group to develop and tap into unique opportunities within the pharmaceutical industry, in order to accelerate Uni-Bio's growth.
Mr. Leung is a Chartered Financial Analyst with a master's degree in pharmacology from the University of Oxford. He has prior experience working in investment banking and biotechnology, and was previously responsible for sourcing, evaluating and executing new growth opportunities. Going forward, Mr. Leung will primarily be responsible for steering the Group's business development activities.
Dr. Firth is the Chief Executive Officer and Founder of ASLAN Pharmaceuticals Pte Ltd., a leading Asia biotech company headquartered in Singapore, and was previously the Head of Asia Healthcare at Bank of America Merrill Lynch. Prior to banking, Dr. Firth worked for a multinational pharmaceutical company for 9 years, including 4 years in the Asia-Pacific region and China, responsible for business development and strategic planning. Dr. Firth is one of the rising stars of the industry: he was recently nominated as one of SCRIPS top 10 pharmaceutical leaders alongside top C-level executives from multinational pharmaceutical companies. Dr Firth holds a PhD from Cambridge University and an Executive MBA from London Business School.
The additional appointment of Mr. Zhao Zhi Gang as an independent non-executive Director on 1 April 2014 will significantly boost the Group's corporate governance standards. During his more than 20 years of experience in corporate finance and audit practice, Mr. Zhao had also held senior financial positions with several publicly listed companies in the United States. His tenure as Chief Financial Officer of Simcere Pharmaceutical Group, one of the largest pharmaceutical players in China, and Kingmed Center for Clinical Laboratories, a leading company in China that provides comprehensive laboratory testing services, will also prove advantageous to the Group in driving regional expansion within the biotechnology industry and improving its corporate governance.
Finally, the Group has strengthened their senior management team by appointing Mr. Koh Phee-Wah as the Chief Executive Officer of the Group's subsidiary, Uni-Bio Science Healthcare. Mr. Koh will be in charge of managing all the Group's biotech operations. Mr. Koh has more than 15 years of general manager experience in a number of multinational life science companies, such as Becton Dickinson, Pharmacia and Monsanto, and also previously led drug product launches in South East Asia and China. Prior to Uni-Bio, Mr. Koh was the Chief Operating Officer of UCB Biopharma China, where he successfully expanded the company's regional sales and marketing footprint. UCB is one of the top 15 global biotechnology companies by market capitalization. With his extensive experience in general management and knowledge in pharmaceutical sales and marketing, Mr Koh is well suited to driving the launch of the Group's future products, including rExtendin-4 and rhPTH 1-34. Mr. Koh graduated from the National University of Singapore and holds a MBA from Washington University. He also qualified as a Chartered Accountant of Australia and New Zealand.
Mr. Tong Kit Shing, Chairman and Executive Director of Uni-Bio Science Group said, "I am delighted with the appointment of the new members of our Board of Directors and senior management team. Their proven experience and industry expertise will strengthen our business foundation. The Group is now evaluating its business development direction and areas of high potential within the pharmaceutical industry, leveraging our business ties and expertise in the PRC market while also considering setting up strategic alliances from overseas markets."
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre located in Dongguan, PRC is fully equipped with a complete system for the development of genetically engineered products with a pilot plant test base which is in line with GMP requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. Both operations in Beijing and Shenzhen produce and distribute their own pharmaceutical products. Starting in 2012, the Group has shifted its focus to biotechnology products.
Contact :Strategic Financial Relations Limited
Veron Ng Phone: +852 2864 4831 Email: veron.ng@sprg.com.hk
Angelus Lau Phone: +852 2864 4805 Email: angelus.lau@sprg.com.hk
Kate Kwan Phone: +852 2864 4873 Email: kate.kwan@sprg.com.hk
Fax: +852 2527 1196
Copyright 2014 ACN Newswire. All rights reserved. www.acnnewswire.com Reported by ACN Newswire 53 minutes ago.
Hong Kong, Apr 1, 2014 - (ACN Newswire) - Uni-Bio Science Group Limited ("Uni-Bio" or the "Group") (SEHK code: 690) strengthened the composition of the Board of Directors ("Board") and senior management team to enhance business fundamentals and to initiate new business development strategies. Operation and business restructuring initiatives will further optimise the Group's operations, providing a stronger platform to drive business growth.
Following the appointment of Mr. Kingsley Leung as an executive Director in February, Dr. Carl Firth and Mr. Zhao Zhi Gang have been appointed as independent non-executive Directors on 1 April 2014. Mr. Leung, Mr. Zhao and Dr. Firth have strong backgrounds in pharmaceuticals and biotechnology, and their industry and professional knowledge will enable the Group to develop and tap into unique opportunities within the pharmaceutical industry, in order to accelerate Uni-Bio's growth.
Mr. Leung is a Chartered Financial Analyst with a master's degree in pharmacology from the University of Oxford. He has prior experience working in investment banking and biotechnology, and was previously responsible for sourcing, evaluating and executing new growth opportunities. Going forward, Mr. Leung will primarily be responsible for steering the Group's business development activities.
Dr. Firth is the Chief Executive Officer and Founder of ASLAN Pharmaceuticals Pte Ltd., a leading Asia biotech company headquartered in Singapore, and was previously the Head of Asia Healthcare at Bank of America Merrill Lynch. Prior to banking, Dr. Firth worked for a multinational pharmaceutical company for 9 years, including 4 years in the Asia-Pacific region and China, responsible for business development and strategic planning. Dr. Firth is one of the rising stars of the industry: he was recently nominated as one of SCRIPS top 10 pharmaceutical leaders alongside top C-level executives from multinational pharmaceutical companies. Dr Firth holds a PhD from Cambridge University and an Executive MBA from London Business School.
The additional appointment of Mr. Zhao Zhi Gang as an independent non-executive Director on 1 April 2014 will significantly boost the Group's corporate governance standards. During his more than 20 years of experience in corporate finance and audit practice, Mr. Zhao had also held senior financial positions with several publicly listed companies in the United States. His tenure as Chief Financial Officer of Simcere Pharmaceutical Group, one of the largest pharmaceutical players in China, and Kingmed Center for Clinical Laboratories, a leading company in China that provides comprehensive laboratory testing services, will also prove advantageous to the Group in driving regional expansion within the biotechnology industry and improving its corporate governance.
Finally, the Group has strengthened their senior management team by appointing Mr. Koh Phee-Wah as the Chief Executive Officer of the Group's subsidiary, Uni-Bio Science Healthcare. Mr. Koh will be in charge of managing all the Group's biotech operations. Mr. Koh has more than 15 years of general manager experience in a number of multinational life science companies, such as Becton Dickinson, Pharmacia and Monsanto, and also previously led drug product launches in South East Asia and China. Prior to Uni-Bio, Mr. Koh was the Chief Operating Officer of UCB Biopharma China, where he successfully expanded the company's regional sales and marketing footprint. UCB is one of the top 15 global biotechnology companies by market capitalization. With his extensive experience in general management and knowledge in pharmaceutical sales and marketing, Mr Koh is well suited to driving the launch of the Group's future products, including rExtendin-4 and rhPTH 1-34. Mr. Koh graduated from the National University of Singapore and holds a MBA from Washington University. He also qualified as a Chartered Accountant of Australia and New Zealand.
Mr. Tong Kit Shing, Chairman and Executive Director of Uni-Bio Science Group said, "I am delighted with the appointment of the new members of our Board of Directors and senior management team. Their proven experience and industry expertise will strengthen our business foundation. The Group is now evaluating its business development direction and areas of high potential within the pharmaceutical industry, leveraging our business ties and expertise in the PRC market while also considering setting up strategic alliances from overseas markets."
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre located in Dongguan, PRC is fully equipped with a complete system for the development of genetically engineered products with a pilot plant test base which is in line with GMP requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. Both operations in Beijing and Shenzhen produce and distribute their own pharmaceutical products. Starting in 2012, the Group has shifted its focus to biotechnology products.
Contact :Strategic Financial Relations Limited
Veron Ng Phone: +852 2864 4831 Email: veron.ng@sprg.com.hk
Angelus Lau Phone: +852 2864 4805 Email: angelus.lau@sprg.com.hk
Kate Kwan Phone: +852 2864 4873 Email: kate.kwan@sprg.com.hk
Fax: +852 2527 1196
Copyright 2014 ACN Newswire. All rights reserved. www.acnnewswire.com Reported by ACN Newswire 53 minutes ago.